📰 Bgne News
Page 3 - Bgne News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bgne. Real-time updates on events, politics, business and more.
October 17, 2023
By Ben Glickman BeiGene's trial of the use of tislelizumab to treat resectable non-small cell lung cancer, when combined with chemotherapy, reached its dual...
October 13, 2023
By Denny Jacob BeiGene's brukinsa received a positive opinion recommending its approval from an European Medicines Agency committee. The biotechnology...
October 9, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year target price among […]
October 7, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among brokerages […]
September 26, 2023
BeiGene (NASDAQ:BGNE – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday. BGNE has been the subject of several other reports. 22nd Century Group reaffirmed a “downgrade” rating on shares of BeiGene in a research note on Friday, […]
September 25, 2023
BeiGene (NASDAQ:BGNE – Free Report) had its price objective hoisted by Citigroup from $285.00 to $290.00 in a research note released on Thursday morning, Marketbeat.com reports. Citigroup currently has a buy rating on the stock. A number of other analysts have also recently weighed in on BGNE. 22nd Century Group reiterated a downgrade rating on […]
September 12, 2023
Stock analysts at Royal Bank of Canada started coverage on shares of BeiGene (NASDAQ:BGNE – Get Free Report) in a research note issued to investors on Tuesday, Benzinga reports. The firm set an “outperform” rating and a $259.00 price target on the stock. Royal Bank of Canada’s price target would suggest a potential upside of […]
September 11, 2023
Analysts at Macquarie assumed coverage on shares of BeiGene (NASDAQ:BGNE – Get Free Report) in a research note issued on Monday, FlyOnTheWall reports. The firm set an “outperform” rating on the stock. BGNE has been the topic of several other research reports. Morgan Stanley decreased their price objective on BeiGene from $321.00 to $319.00 and […]
September 1, 2023
BeiGene (NASDAQ:BGNE – Free Report) had its price target cut by Morgan Stanley from $321.00 to $319.00 in a research note released on Tuesday, Benzinga reports. They currently have an overweight rating on the stock. A number of other analysts have also weighed in on BGNE. 22nd Century Group reaffirmed a downgrade rating on shares […]
August 19, 2023
StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Get Free Report) in a research note issued to investors on Thursday. The firm set a “hold” rating on the stock. Other analysts have also issued research reports about the company. JPMorgan Chase & Co. upped their price objective on BeiGene from $297.00 to $300.00 and […]